“Why is weight-loss achievement the holy grail of drug development?” 

In the premiere episode of Pharmland, co-hosts Bradley Nelson and Tom Davies talk with RxBenefits clinical pharmacist Langley Kyle, PharmD, about the use of GLP-1 drugs for weight-loss purposes — and discuss society’s changing attitudes toward obesity. As the healthcare industry comes to recognize obesity as a treatable health condition rather than a personal failing, plan sponsors find themselves examining their position on covering weight-loss medications as a class. And as GLP-1s originally indicated for type 2 diabetes are increasingly used for weight-management purposes, that decision — to cover, or not to cover? — becomes increasingly pricey. 

You can also subscribe to any of these podcast platforms to receive notifications on new episodes.